3222 related articles for article (PubMed ID: 25485915)
21. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
22. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Kahn SR; Springmann V; Schulman S; Martineau J; Stewart JA; Komari N; McLeod A; Strulovitch C; Blostein M; Faucher JP; Gamble G; Gordon W; Kagoma PK; Miron MJ; Laverdière D; Game M; Mills A
Thromb Haemost; 2012 Sep; 108(3):493-8. PubMed ID: 22782073
[TBL] [Abstract][Full Text] [Related]
23. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
Kwiatt ME; Patel MS; Ross SE; Lachant MT; MacNew HG; Ochsner MG; Norwood SH; Speier L; Kozar R; Gerber JA; Rowell S; Krishnakumar S; Livingston DH; Manis G; Haan JM
J Trauma Acute Care Surg; 2012 Sep; 73(3):625-8. PubMed ID: 22929493
[TBL] [Abstract][Full Text] [Related]
24. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
25. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
26. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients.
Tagalakis V; Wharin C; Kahn SR
Semin Thromb Hemost; 2013 Mar; 39(2):127-40. PubMed ID: 23386467
[TBL] [Abstract][Full Text] [Related]
28. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
[TBL] [Abstract][Full Text] [Related]
30. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
32. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
[TBL] [Abstract][Full Text] [Related]
33. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with recurrent venous thromboembolism in patients with malignant disease.
Lin J; Proctor MC; Varma M; Greenfield LJ; Upchurch GR; Henke PK
J Vasc Surg; 2003 May; 37(5):976-83. PubMed ID: 12756342
[TBL] [Abstract][Full Text] [Related]
35. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.
Noble SI; Shelley MD; Coles B; Williams SM; Wilcock A; Johnson MJ;
Lancet Oncol; 2008 Jun; 9(6):577-84. PubMed ID: 18510989
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of venous thromboembolic disease in cancer patients].
Farge-Bancel D; Florea L; Bosquet L; Debourdeau P
Pathol Biol (Paris); 2008 Jun; 56(4):220-8. PubMed ID: 18394821
[TBL] [Abstract][Full Text] [Related]
37. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients.
Jones KL; Barnett C; Gauthier M; Boster B; Espirito JL; Michaud LB
J Oncol Pharm Pract; 2012 Mar; 18(1):122-7. PubMed ID: 21364079
[TBL] [Abstract][Full Text] [Related]
39. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
Harrington DW
Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
[TBL] [Abstract][Full Text] [Related]
40. Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries.
Ahmed HY; Papali A; Haile T; Shrestha GS; Schultz MJ; Lundeg G; Akrami KM;
Am J Trop Med Hyg; 2021 Jan; 104(3_Suppl):99-109. PubMed ID: 33432908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
